Citation
Kim, Jongwoo, et al. "Enhancing Effect of HT008-1 On Cognitive Function and Quality of Life in Cognitively Declined Healthy Adults: a Randomized, Double-blind, Placebo-controlled, Trial." Pharmacology, Biochemistry, and Behavior, vol. 90, no. 4, 2008, pp. 517-24.
Kim J, Chung SY, Park S, et al. Enhancing effect of HT008-1 on cognitive function and quality of life in cognitively declined healthy adults: a randomized, double-blind, placebo-controlled, trial. Pharmacol Biochem Behav. 2008;90(4):517-24.
Kim, J., Chung, S. Y., Park, S., Park, J. H., Byun, S., Hwang, M., Oh, D. S., Choi, H., Kim, M. Y., Bu, Y. C., Doré, S., Whang, W. W., & Kim, H. (2008). Enhancing effect of HT008-1 on cognitive function and quality of life in cognitively declined healthy adults: a randomized, double-blind, placebo-controlled, trial. Pharmacology, Biochemistry, and Behavior, 90(4), 517-24. https://doi.org/10.1016/j.pbb.2008.03.033
Kim J, et al. Enhancing Effect of HT008-1 On Cognitive Function and Quality of Life in Cognitively Declined Healthy Adults: a Randomized, Double-blind, Placebo-controlled, Trial. Pharmacol Biochem Behav. 2008;90(4):517-24. PubMed PMID: 18550156.
TY - JOUR
T1 - Enhancing effect of HT008-1 on cognitive function and quality of life in cognitively declined healthy adults: a randomized, double-blind, placebo-controlled, trial.
AU - Kim,Jongwoo,
AU - Chung,Sun Yong,
AU - Park,Sojeong,
AU - Park,Jong-Hoon,
AU - Byun,Soonim,
AU - Hwang,Manki,
AU - Oh,Dal-Seok,
AU - Choi,Hyungsuk,
AU - Kim,Mi-Yeon,
AU - Bu,Youngmin C,
AU - Doré,Sylvain,
AU - Whang,Wei-Wan,
AU - Kim,Hocheol,
PY - 2007/08/30/received
PY - 2008/03/15/revised
PY - 2008/03/30/accepted
PY - 2008/6/14/pubmed
PY - 2008/12/17/medline
PY - 2008/6/14/entrez
SP - 517
EP - 24
JF - Pharmacology, biochemistry, and behavior
JO - Pharmacol Biochem Behav
VL - 90
IS - 4
N2 - HT008-1 is one of the most effective multiherb mixtures that have neuroprotective effects in traditional Korean medicine. The purpose of this study was to conduct a clinical trial of the efficacy of HT008-1 on the neuropsychological functioning and quality of life (QoL) in cognitively intact adults. One hundred and eighteen male (n - 42) and female (n = 76) volunteers who reported no history of dementia or significant neurocognitive impairments and obtained Korean Version of Mini Mental State Examination total scores of at least 24 were examined via an 8-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group, clinical trial. Participants were randomly assigned to receive either HT008-1 (n = 59) or placebo (n = 59) for 8 weeks. Efficacy measures consisted of participants' performance scores from pretreatment baseline to those obtained just before termination of treatment on standardized neuropsychological measures from the subsets of Wechsler Memory Scale-III (WMS-III). QoL was assessed by subjective questionnaires WHOQoL-Bref about five categories. Participants who scored in the lower third of the Auditory recognition delayed at baseline and received HT008-1 exhibited improvement on the WMS-III Auditory recognition delayed subtest compared with placebo controls. The HT008-1 group also improved on general health scores in the QoL test.
SN - 0091-3057
UR - https://www.unboundmedicine.com/medline/citation/18550156/Enhancing_effect_of_HT008-1_on_cognitive_function_and_quality_of_life_in_cognitively_declined_healthy_adults:_a_randomized,_double-blind,_placebo-controlled,_trial.
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091-3057(08)00116-0
DB - PRIME
DP - Unbound Medicine
ER -
